Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients
Nirmatrelvir-ritonavir effectively lowers hospitalization rates and long COVID symptoms in non-hospitalized, high-risk patients with mild to moderate COVID-19.